The willingness of the Saudi Arabian population to participate in the COVID-19 vaccine trial: A case–control study

Abstract

Objectives This study examines the Saudi Arabian population's willingness to participate in clinical trials for the coronavirus disease 2019 (COVID-19) vaccine, comparing recovered cases' willingness with that of healthy volunteers. Methods A case–control study was conducted on the Saudi Arabian population during September 2020. The data were collected from recovered COVID-19 participants as the case group, and healthy volunteers as the control group. Results The data showed that 42.2% (n = 315) of recovered COVID-19 cases were more willing to participate in the COVID-19 vaccine trial than healthy volunteers (299; 38.1%) with a p < 0.001. The proportion of the participants who were willing to donate plasma was significantly higher among recovered participants, 84.2% (n = 112), than healthy volunteers, 76.3% (n = 87), with a p < 0.0001. The most significant factor responsible for a willingness to participate was the belief that vaccine discovery would help scientific developments (r = 0.525 and 0.465 for case and control, respectively). In comparison, significant reasons behind the unwillingness to participate were the risk of exposure to an unproven vaccine, r = 0.377 and 0.497 for case and control, respectively (p < 0.001), and a discomfort with being treated as an experimental subject (r = 0.275 and 0.374 for case and control, respectively). Conclusions The differences in readiness toward the COVID-19 vaccine trial in our study does not indicate any passive exposure of participants to an unproven clinical trial vaccine, nor does it shed light on well-informed risk-related decisions. However, certain factors can significantly influence decision-making while contributing toward clinical research. This study's results must not be used for the individuals' recruitment bias in a COVID-19 vaccine trial.

Factors associated with the intention to participate in COVID-19 vaccine clinical trials: A cross-sectional study in Peru

“… [17] Interestingly, these studies [17] , [18] included recovered COVID-19 cases; therefore, the intention to participate in clinical trials may be overestimated. [20] …”

Facial topical cream promotes facemask tolerability and compliance during COVID-19 pandemic

“…The coronavirus 2019 (COVID-19) pandemic is a lethal viral respiratory infection. 1 , 2 , 3 , 4 , 5 Facemask use by the general population and healthcare workers is a crucial part of managing the pandemic. 5 Short-term and prolonged facemask use may be associated with localised facial skin complications 6 , 7 related to facemask material, moisture, heat, and pressure, 7 , 8 including skin rash, bruising, acne, discomfort, pruritus, indentation, dyspigmentation, hotness, ulceration, redness, crusting, infection, and dermatitis.…”